The National Institutes of Health has finalized new rules to reduce financial conflicts of interests among federally funded researchers who also receive payments or stock from drug and medical device companies. The rules, which will affect more than 40,000 researchers, come after a string of high profile cases where federally funded researchers failed to disclose millions of dollars from companies with a financial interest in the outcome of their work. Read full article >>